Corporate Presentation February 2013 Speed | Innovation | - - PowerPoint PPT Presentation

▶
corporate presentation
SMART_READER_LITE
LIVE PREVIEW

Corporate Presentation February 2013 Speed | Innovation | - - PowerPoint PPT Presentation

Mar 21, 2023 238 likes •535 views

Corporate Presentation February 2013 Speed | Innovation | Happiness Overview Vision Delivering Innovation - Transforming lives Values Speed Innovation Happiness Our constant approach at all levels is to seek better ways of listening,

slide-1
SLIDE 1

Speed | Innovation | Happiness

Corporate Presentation

February 2013

slide-2
SLIDE 2

Speed | Innovation | Happiness

2

Vision

Delivering Innovation - Transforming lives

Values

Speed

Proactive and swift action is our mantra

Innovation

Our constant approach at all levels is to seek better ways of listening, thinking & doing – making our offerings meaningful & impactful

Happiness

We are motivated by our customer’s success & happiness of our stakeholders

Overview

slide-3
SLIDE 3

Speed | Innovation | Happiness

Overview

3

Market position

  • Worlds largest

Pharmaceutical Packaging Company, providing Research based Innovative Packaging Solutions for Solid Dosage Formulations Revenues

  • USD 713 million

Customers

  • Over 2500 customers globally

People

  • Team of over ~1800 strong

professionals globally Global Footprint

  • Facilities in 11 locations across

Europe, US and Asia

slide-4
SLIDE 4

Speed | Innovation | Happiness

4

Facilities in three continents (11 sites with 5 in Europe, 2 in USA and 4 in Asia) provides geographical diversification

Calendaring, Coating and Specialty Flexible Films manufacturing sites World’s largest Polymer Coating & Lamination lines. Pharma Center of Excellence for Asia. Development Center for nCID technologies Calendaring, Lamination and Metallizing manufacturing capability for the European Food Industry Dedicated facility for manufacturing High-end Security ID Cards films Calendaring lines, strategically located to cater the eastern European Markets Manufacturing site for specialized Child Resistant Blister & Shell Packs in joint venture with MeadWestvaco American Center of Excellence for Pharma Packaging Research &

  • Development. Calendering and

Stentering facilities. Security ID card Films manufacturing High-end Specialty Calendared Film for Print and Shrink applications European Center of Excellence for Pharma Packaging Research & Development. Global scale Calendaring, Coating and Lamination facilities

Global Footprints

Global Center of Excellence and R&D Center for Pharmaceutical Packaging Development. Global Clinical Supplies facility for Asian

  • Market. State of the art Polymer

Coating and Aluminum Printing facilities

slide-5
SLIDE 5

Speed | Innovation | Happiness

5

Corporate Structure

Bilcare India

Bilcare Singapore 100% Bilcare Inc. 100% Bilcare Brazil 100% Bilcare GmbH 100% Bilcare SA 100% Bilcare Technologies 80% Bilcare Technologies Italia 92% Bilcare Mauritius 100% Bilcare Research AG 100% Bilcare Research Italia Srl. 100% Bilcare Films Italia Srl. 100% Bilcare Research Inc. 100% Bilcare Research GmbH - 100% Caprihans 51% International Labs 50:50 JV

slide-6
SLIDE 6

Speed | Innovation | Happiness

Innovative Packaging Solutions

Pharma Packaging Innovations Packaging Films Solutions Cards Solutions Specialty Films Solutions

nonClonableIDTM Technologies

Anytime, Anywhere Authentication and Track-and- Trace technology for securitizing people and products

Global Clinical Supplies

Solutions for Clinical Trial Programs; facilitating speed to market - Accelerating drug development process

Business Verticles

6

slide-7
SLIDE 7

Speed | Innovation | Happiness

7

Innovative Packaging Solutions

Integrated R&D consultancy and Solutions for the global pharmaceutical industry Value based solutions for brand protection technologies and next generation packaging needs Highly focused and targeted to address the unmet needs of the pharmaceutical industry Intensive R&D efforts, complemented by excellent product development capabilities Partnerships with external research institutes and experts of repute for establishing strong R&D capabilities Continued investments in R&D as a core element for growth R&D facilities spread across Pune – India, Changi – Singapore; Staufen & Botzingen - Germany

Our R&D Philosophy

slide-8
SLIDE 8

Speed | Innovation | Happiness

Pioneer packaging division of Bilcare Innovative packaging solutions to the Global pharmaceutical industry. Offering a comprehensive range of specialty primary packaging materials Pharma brand building solutions for sustained growth Addressing key challenges of pharma clients on Counterfeit, Compliance, Communication, Convenience and Child resistant packaging Worldwide leaders with Global footprints in Americas, Europe and Asia Over 148 Patents filed worldwide

PHARMA PACKAGING Innovations (PPI)

8

slide-9
SLIDE 9

Speed | Innovation | Happiness

  • First and only scientific packaging development study developed by

Bilcare for the pharmaceutical solid dosage formulations

  • Studies and quantifies degradation pattern of the final formulation

and suggests optimal packaging using software based mathematical modeling

  • Reliable tools to decrease time to market and offers the ability to

select the optimal packaging from the beginning

  • Precursor to stability study

Compliance Counterfeit Communication Convenience Child Resistant

9

Marketing initiatives to address the Pharma brand challenges

PHARMA PACKAGING – Core Offering

slide-10
SLIDE 10

Speed | Innovation | Happiness

Pharma Packaging - Range of products

Bilcare offers a complete range of high-quality packaging films. Our production standards are the highest in the business, with every film meeting complex and ever dynamic pharmaceutical specifications

Flexible Packaging Films

  • Pharma-grade Barrier films
  • Extra

(PVC), Duplex(PVC/PVdC), Triple x (PVC/PE/PVdC), Exel (PVC/PE).

  • Ultra-high Barrier Film
  • Aquaba
  • Zymax TX.
  • Eco-friendly Halogen-free Films
  • Optra, Astra, Petra, Topas

Aluminum Foils

  • Pharma-grade Cold-forming Foil
  • Bilcare Venus (PVC/Alu/OPA)
  • Pharma-grade Aluminium Lidding

foils

  • Bilcare Zeon, Bilcare

Zeon+, Bilcare Zeon xt

  • Eco-friendly Lidding Foils
  • Bilcare Nova, Bilcare

SilNova, Bilcare MetNova

  • Bilcare CR Lidding Foils
  • Bilcare Crispak of various

structures Innovative Products

  • Products to create brand identity

with anti-counterfeiting features

  • Bilcare Patina, Bilcare

Ultra, Bilcare Ultra TX, Bilcare Protect, Bilcare Secure.

  • Flexible Laminates
  • Aclar
  • Bilcare Lamiflex of various

structures of paper, aluminum and polymer film combinations

slide-11
SLIDE 11

Speed | Innovation | Happiness

Global Pharma Packaging Customers

GSK Novartis Merck Sanofi Aventis International Laboratories, Inc. Laboratorios Leti S.A. Reckitt Benckiser Healthcare Laboratórios Cinfa, S.A. Zaklady CILAG AstraZeneca Bristol-Myers Squibb Pfizer Bluepharma Bayer Delpharm Catalent Johnson & Johnson

Pharma Packaging Customers - Global

11

slide-12
SLIDE 12

Speed | Innovation | Happiness

Packaging Films Solutions (PFS)

Leading suppliers of wide range

  • f rigid Mono and Multilayer

films for Food & FMCG industry 12

Cards Solutions (CS)

High quality cores and overlays for all kind of PVC Laminate Cards viz. Magnetic swipe cards, Gift & Loyalty cards, Banking Cards, Playing cards etc.

Specialty Films Solutions (SFS)

High quality Films for sectors such as Printing/ Decoration, Shrink films, Visual packaging, Technical applications, Office materials and Furniture

slide-13
SLIDE 13

Speed | Innovation | Happiness

13 Highly differentiated, next-gen anti-counterfeiting solution Large market

  • pportunity

(approx 5% to 7%

  • f the entire World

trade is feared to be counterfeit *) Globally patented proprietary technology having applications beyond anti- counterfeiting Nationally and internationally recognized (Pioneer status from Govt. of Singapore) Razor sharp focus

  • n operations

(Production capacity of over 1 Billion Chips ) Strong partner/channel focus to drive scale quickly Highly experienced, talen ted and focused leadership team

…

* http://www.unc.edu/courses/2010spring/law/357c/001/ACG/stats.html

nCID Technologies – for Brand Safety & Security

13

slide-14
SLIDE 14

Speed | Innovation | Happiness

The nonClonableID Chip cannot be duplicated ever!

Bilcare’s answer for Counterfeiting

14 Metal materials- based “Signature” of micro nano particles Serial Number 2D Data Matrix assigned to each Signature

nonClonable

Tamper -proof Chip for Identification & Authentication Captured by MO-Chip reader & stored in Digitized form

slide-15
SLIDE 15

Speed | Innovation | Happiness

Scanners and Mobile Device

Auto Components Textile label

Client portal Wine & Beverages Pharma Currency

Application across Industries

15 Central Server Tamper evident nCID Chip ID / Warranty / Loyalty cards

slide-16
SLIDE 16

Speed | Innovation | Happiness

nCID Technology - Business Impact

16

slide-17
SLIDE 17

Speed | Innovation | Happiness

17

Global Clinical Supplies (GCS)

Bilcare GCS delivers end-to-end solution that supports a Drug through the entire Clinical Trial life cycle From pre-formulation to return & destruction accountability, our integrated

  • fferings are aimed at establishing our customer’s critical success factor –

speed to market

slide-18
SLIDE 18

Speed | Innovation | Happiness

TRUST TRUST

Services

Formulation development Analytical & Research Services Clinical Manufact., Pa ckaging & Labeling Interactive Voice & Web Response System Global Logistics & Supply Chain Management Depot Management QP Services Comparator Sourcing In-sourcing CTM Services

QUALITY FOUNDATION & INNOVATION

Bilcare GCS Service Offerings

18

slide-19
SLIDE 19

Speed | Innovation | Happiness

19

Bilcare GCS Facilities

FDA licensed facility to carry out CTMS activities like Manufacturing, Packaging & Labeling, Storage & Distribution operations of clinical trial supplies World class SOPs in line with USFDA & MHRA requirements GCS Facilities - India

Packaging & Labeling facility Storage & Distribution Bilcare GCS – Global S&D Network In Aug 2012, United Drugs Plc acquired Bilcare’s Global Clinical Supplies business in US and UK for USD 61 Mn. while Bilcare retained its GCS Asia business. Going forward, Bilcare GCS, Asia and United Drugs Plc. will work together to use their complementary resources to meet the needs of their global customers across US, Europe and Asia.

slide-20
SLIDE 20

Speed | Innovation | Happiness

Financial Overview

20

India

80%

Overseas 20%

Revenue Share 2007

India 53% Overseas 47%

Revenue Share 2010

India 20%

Overseas 80%

Revenue Share 2012

Share of International Business grown from 20% to 80% in the last 5 years

Transformation to a Global Company

Note: The above years denote Financial Year ending 31st March for that particular year

slide-21
SLIDE 21

Speed | Innovation | Happiness

Key Financial Parameters – P&L CONSOLIDATED (updated till 31st March 2012)

21

131 169 208 455 713 100 200 300 400 500 600 700 800 2008 2009 2010 2011 2012

Revenue (USD Mn.)

32 38 51 74 95 20 40 60 80 100 2008 2009 2010 2011 2012

EBIDTA (USD Mn.) Note: The above years denote Financial Year ending 31st March for that particular year 10 20 30 40 50 60 2008 2009 2010 2011 2012 16 16 23 29 27 21 24 33 46 52 PAT Cash accruals PAT & Cash Accruals (USD Mn.)

4.9 5.9 4.1 2.9

  • 1.0

2.0 3.0 4.0 5.0 6.0 7.0 2009 2010 2011 2012

Interest Cover (Times)

0.63 0.82 0.96 1.24 1.16 0.00 0.20 0.40 0.60 0.80 1.00 1.20 1.40 2008 2009 2010 2011 2012

Earning Per Share (USD/ share)

slide-22
SLIDE 22

Speed | Innovation | Happiness

Profit & Loss Account CONSOLIDATED

22

USD Mn.

Particulars 31-Mar-10 31-Mar-11 31-Mar-12 Apr-June 2012 July-Sep 2012 Oct – Dec 2012

Audited Unaudited Revenue (incl. other income) 208.33 455.20 713.34 182.29 187.69 175.27 Contribution 92.79 200.15 304.98 77.21 77.31 72.93 % of Revenue 45% 44% 43% 42% 41% 42 Fixed Expenses 41.99 126.47 210.37 55.52 52.70 48.45 EBIDTA 50.80 73.67 94.61 21.69 24.61 24.48 % of Revenue 24% 16% 13% 12% 13% 14% Interest 8.58 17.93 32.15 8.23 8.16 7.83 Depreciation 53.55 16.79 25.62 6.37 6.13 6.86 PBT 31.76 39.08 36.84 7.09 10.32 9.79 Tax 8.90 9.73 9.46 1.15 1.92 1.86 PAT 22.86 29.21 27.38 5.94 8.40 7.93

slide-23
SLIDE 23

Speed | Innovation | Happiness

23

Note: The above years denote Financial Year ending 31st March for that particular year

Key Financial Parameters – Balance Sheet CONSOLIDATED (updated till 31st March 2012)

97 171 218 261 50 100 150 200 250 300 2009 2010 2011 2012

Networth (USD Mn.)

1.92 0.69 1.01 1.03 0.00 0.50 1.00 1.50 2.00 2.50 2009 2010 2011 2012

Debt/ Equity Ratio

0.0% 2.0% 4.0% 6.0% 8.0% 10.0% 12.0% 14.0% 16.0% 2009 2010 2011 2012 15.8% 11.5% 10.9% 11.2%

Return on Capital Employed

  • 0.20

0.40 0.60 0.80 1.00 1.20 2009 2010 2011 2012 0.46 1.17 0.60 0.96

Total Outside Liab/ Total Net Worth

slide-24
SLIDE 24

Speed | Innovation | Happiness

Balance Sheet CONSOLIDATED

24

USD Mn.

Particulars 31-Mar-10 31-Mar-11 31-Mar-12 30-09-2012 Audited Unaudited

Equity Capital 4.44 4.60 4.60 4.60 Networth (inccl. deferred tax) 189.03 244.00 301.67 317.84 Debt 117.15 238.42 267.90 275.69 TOTAL 310.62 487.02 574.17 598.13 Net Fixed Assets 173.56 282.24 320.01 305.97 Investments 0.00 0.04 0.02 23.35 Net Current Assets 137.06 204.74 254.14 268.8 TOTAL 310.62 487.02 574.17 598.13

slide-25
SLIDE 25

Speed | Innovation | Happiness

25

Note: The above years denote Financial Year ending 31st March for that particular year

Key Financial Parameters – P&L STANDALONE INDIA (updated till 31st March 2012)

83 93 110 130 148 20 40 60 80 100 120 140 160 2008 2009 2010 2011 2012

Revenue (USD Mn.)

25 26 32 39 45 20 40 60 2008 2009 2010 2011 2012

EBIDTA (USD Mn.)

30% 27% 29% 30% 30% 24% 26% 28% 30% 32% 2008 2009 2010 2011 2012

% margin

15 16 20 23 22 10 20 30 2008 2009 2010 2011 2012

Cash Accrual (USD Mn.)

12 12 15 17 15 5 10 15 20 2008 2009 2010 2011 2012

PAT (USD Mn.)

slide-26
SLIDE 26

Speed | Innovation | Happiness

26

Profit & Loss Account Standalone India

USD Mn.

Particulars 31-Mar-10 31-Mar-11 31-Mar-12 Apr-June 2012 July-Sep 2012 Oct-Dec 2012 Audited

Unaudited Revenue (incl. other income) 110.32 129.57 148.33 34.80 41.32 41.40 Contribution 44.38 52.05 57.19 12.08 14.64 14.87 % of Revenue 40% 40% 39% 35% 35% 36% Fixed Expenses 11.98 12.95 12.45 3.21 3.40 3.14 EBIDTA 32.40 39.17 44.74 8.87 11.25 11.74 % of Revenue 29% 30% 30% 25% 27% 28% Interest 5.16 8.77 15.58 4.88 4.99 5.16 Depreciation 5.17 5.80 7.04 1.78 1.78 1.78 PBT 22.07 24.60 22.12 2.20 4.47 4.79 Tax 7.31 7.58 7.51 0.72 1.45 1.55 PAT 14.75 17.01 14.61 1.48 3.02 3.23

slide-27
SLIDE 27

Speed | Innovation | Happiness

27

42 72 84 153 176 187 20 40 60 80 100 120 140 160 180 200 2007 2008 2009 2010 2011 2012

Networth (USD Mn.)

Note: The above years denote Financial Year ending 31st March for that particular year

Key Financial Parameters – Balance Sheet INDIA STANDALONE (updated till 31st March 2012)

1.10 0.56 0.60 0.68 0.00 0.20 0.40 0.60 0.80 1.00 1.20 2009 2010 2011 2012

Debt Equity Ratio

slide-28
SLIDE 28

Speed | Innovation | Happiness

Balance Sheet Standalone India

28

USD Mn.

Particulars 31-Mar-10 31-Mar-11 31-Mar-12 30-09-2012 Audited Unaudited

Equity Capital 4.44 4.60 4.60 4.60 Reserves & Surplus (inccl. deferred tax) 166.21 191.28 204.03 210.05 Debt 86.17 106.08 126.86 130.92 TOTAL 256.81 301.97 335.49 345.57 Net Fixed Assets 86.96 99.90 118.88 136.25 Investments 93.73 128.44 132.79 134.59 Net Current Assets 76.12 73.62 83.82 74.73 TOTAL 256.81 301.97 335.49 345.57

slide-29
SLIDE 29

Speed | Innovation | Happiness

Bilcare Limited

Worlds largest Pharmaceutical Packaging Company Business in over 50 countries worldwide, and growing Patented nCID Technology under commercialization Focus on Research & technology Strong Assets base and Profitability numbers 29

Bilcare Limited, 601, ICC Trade Tower, Pune, India (Corporate office) www.bilcare.com